Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Asahi Kasai to Integrate Japan and US Pharma Biz by March 2026
Asahi Kasei plans to integrate its pharmaceutical businesses in Japan and the US. The transition to the new scheme has already gotten underway since this fiscal year, with the company aiming to complete the process by the end of March…
To read the full story
Related Article
- Asahi Kasei Pharma Confident of Hitting FY2030 Group Sales Target: President
December 10, 2025
- Asahi Kasei to Buy Calliditas, Bag 1st Therapy for IgA Nephropathy
May 29, 2024
- Asahi Kasei Completes Acquisition of Veloxis
March 5, 2020
BUSINESS
- MSD Urges Swift Rollout of Routine HPV Vaccination for Males in Japan
July 29, 2026
- Takeda Files Entyvio IV for Pediatric Use, New Adult Dosing in Japan
July 29, 2026
- Japan OTC Market Falls for 4th Straight Month in June: Intage
July 29, 2026
- J-TEC, OSferionBiomaterials Join Forces to Expand Knee OA Business
July 29, 2026
- FunPep Allergy Vaccine Misses Exploratory Efficacy Goals in PI
July 29, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…